Melanotan I vs PTD-DBM
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Afamelanotide, Scenesse
Melanotan I is the research name for afamelanotide, a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. It is the only melanocortin peptide with regulatory approval: sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). It is given as a 16 mg bioresorbable implant under the skin by a clinician, not as a tanning shortcut.
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Key Comparison Insights
- Melanotan I is FDA approved, while PTD-DBM remains in research stages.
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Melanotan I has stronger research evidence (FDA Approved) compared to PTD-DBM (Animal Studies).
Detailed Comparison
| Attribute | Melanotan I | PTD-DBM |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent. | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. |
| Common Dosing | 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) Daily during loading (1-2 weeks), then 1-2x weekly maintenance | No official dose. Sold as 1 mg or 5 mg vials, or a ready-made ~0.001% topical spray Once daily to the scalp in most community routines |
| Administration | Subcutaneous implant (not injection) | Topical (applied to skin) in published research; usually co-applied with valproic acid |
| Typical Duration | Long-term / as needed before sun season | Applied over several weeks in animal studies |
| Best Time to Take | Evening or before sun exposure | Not established (topical in animal studies) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with gold-standard human evidence. The pivotal data came from two multicenter, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2015 (Langendonk et al., 373(1):48-59), enrolling 168 EPP patients across the EU and US who received the 16 mg implant or placebo every 60 days. Afamelanotide significantly increased pain-free time in sunlight (for example, median 69.4 vs 40.8 hours in the US trial), reduced phototoxic reactions, and improved disease-specific quality of life, with mostly mild adverse events. Long-term observational follow-up of EPP patients has supported continued benefit and an acceptable safety profile. The big caveats: this approval is narrowly for EPP, not for cosmetic tanning, and the unregulated injectable 'Melanotan' products people buy online are not the same controlled, clinician-administered implant and carry real risks. Bottom line: a genuinely proven, approved drug for a rare condition, frequently misused outside that lane. | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a combination of 2 mM PTD-DBM and 500 mM valproic acid outperformed 100 mM minoxidil in that model (mM means millimolar, which describes how concentrated the topical liquid was, not a milligram dose). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. |
Frequently Asked Questions: Melanotan I vs PTD-DBM
What is the difference between Melanotan I and PTD-DBM?
Melanotan I is a skin & hair peptide that melanotan i is the research name for afamelanotide, a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-msh), also written as [nle4, d-phe7]-alpha-msh or ndp-msh. it is the only melanocortin peptide with regulatory approval: sold as scenesse, it was approved by the ema in 2014 and the fda in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (epp). it is given as a 16 mg bioresorbable implant under the skin by a clinician, not as a tanning shortcut. PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Melanotan I or PTD-DBM?
Neither is universally "better" - the choice depends on your specific goals. Melanotan I is typically used for skin & hair purposes, while PTD-DBM is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Melanotan I and PTD-DBM be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Melanotan I and PTD-DBM together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.